Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

Loghavi Sanam; Pemmaraju Naveen; Kanagal-Shamanna Rashmi; Mehrotra Meenakshi; Medeiros L. Jeffrey; Luthra Raja; Lin Pei; Huh Yang; Kantarjian Hagop M.; Cortes Jorge E.; Verstovsek Srdan; Patel Keyur P.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

【24h】

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

机译：抗酪氨酸激酶抑制剂治疗罕见髓鞘抑制剂治疗的洞察力伴有CALR突变和BCR-ABL1

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2015年第21期| 共6页
作者
Loghavi Sanam; Pemmaraju Naveen; Kanagal-Shamanna Rashmi; Mehrotra Meenakshi; Medeiros L. Jeffrey; Luthra Raja; Lin Pei; Huh Yang; Kantarjian Hagop M.; Cortes Jorge E.; Verstovsek Srdan; Patel Keyur P.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Hematopathol Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1 [J] . Loghavi Sanam, Pemmaraju Naveen, Kanagal-Shamanna Rashmi, Blood: The Journal of the American Society of Hematology . 2015 ,第21期

机译：抗酪氨酸激酶抑制剂治疗罕见髓鞘抑制剂治疗的洞察力伴有CALR突变和BCR-ABL1
2. Coexistence of JAK2 JAK2 or CALR CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors [J] . Lewandowski K., Gniot M., Wojtaszewska M., International journal of laboratory hematology . 2018 ,第3期

机译：JAK2 JAK2或CALR CALR突变的共存是一种罕见但在用酪氨酸激酶抑制剂治疗的慢性骨髓性白血病患者中罕见但临床重要事件
3. Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 "co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response [J] . Gerlach Magdalena M., Lundberg Pontus, Halter Joerg, Leukemia and lymphoma . 2018 ,第7a8期

机译：骨髓肿瘤中的克隆因子与形态发生突变：U2AF1，TET2，CSF3R和JAK2“共突变”肌酚肌肉瘤中的年代观察表明激酶抑制剂治疗反应的突变和潜在预测值的分层顺序。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. The clinical and pathological significance of calreticulin gene mutations in chronic myeloproliferative neoplasms [D] . Elgumati, Omyma Mohamed 2015

机译：慢性骨髓增生性肿瘤钙网蛋白基因突变的临床和病理意义
6. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients [O] . Vaclava Polivkova, Peter Rohon, Hana Klamova, -1

机译：再谈干扰素-α：个体化治疗管理减轻了酪氨酸激酶抑制剂对BCR-ABL1突变的选择性压力导致高危CML患者发生分子反应
7. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. [O] . Vaclava Polivkova, Peter Rohon, Hana Klamova, 2016

机译：干扰素-α重访：个体化治疗管理缓解了酪氨酸激酶抑制剂对BCR-aBL1突变的选择压力，导致高风险CmL患者的分子反应。

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

著录项

相似文献

相关主题

期刊订阅